Researchers from KU Leuven, the University of California Davis Medical Center, the University of Cologne, and over 20 collaborating institutions report that the antifungal olorofim demonstrated efficacy and tolerability in patients with invasive fungal disease who had exhausted most other treatment options.
Olorofim Phase IIb trial shows efficacy in invasive fungal disease for patients with limited treatment options
